COVID-19 vaccines have prevented 7.2 million infections and 27,000 deaths in England alone

Latest modelling analysis from Public Health England (PHE) and the University of Cambridge’s MRC Biostatistics Unit suggests that the coronavirus (COVID-19) vaccination programme has so far prevented an estimated 7.2 million infections and 27,000 deaths in England alone.

This is the first analysis giving an estimated number of vaccine-prevented infections, providing further evidence of the staggering impact of the vaccination programme so far.

PHE Head of Immunisation Dr Mary Ramsay said: "These findings remind us once again why getting both doses of your vaccine is the most important thing you can do to stop the spread of this terrible disease.

"As well as preventing the deaths of tens of thousands from COVID-19, for the first time we can now appreciate the huge impact that the vaccines have had on stopping people getting infected, and therefore passing the virus on to others."

The results were produced using the PHE and Cambridge real-time pandemic surveillance model, looking at the direct and indirect impact of the COVID-19 vaccination programme on infections and mortality.

The total was calculated by comparing the estimated impact of vaccination on infection and mortality against a worst-case scenario where no vaccines were in place to reduce infections and mortality.

Dr Paul Birrell, Senior Research Associate at the MRC Biostatistics Unit, University of Cambridge and Senior Principal Modeller at PHE, said: "The number of infections and deaths saved by the vaccination programme is not only astoundingly high, but continues to grow exponentially as the vaccination programme continues.

"In practice, this analysis highlights that the vaccination programme has given us a path back towards a normal life that wouldn’t otherwise have been possible. This is why it’s so important that we all get 2 doses of the vaccine as soon as we can."

Most Popular Now

CDC COVID-19 study shows mRNA vaccines reduce risk…

A new CDC study finds the mRNA COVID-19 vaccines authorized by the Food and Drug Administration (Pfizer-BioNTech and Moderna) reduce the risk of infection by 91 percent f...

Novartis and Molecular Partners announce start of …

Novartis and Molecular Partners announced the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate en...

An omega-3 that's poison for tumors

So-called "good fatty acids" are essential for human health and much sought after by those who try to eat healthily. Among the Omega-3 fatty acids, DHA or docosahexaenoic...

Pfizer and BioNTech receive first authorization in…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been exp...

Protein identified as new therapeutic anti-viral t…

New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral...

Pfizer and BioNTech to provide 500 million doses o…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies' ...

Bayer to advance two first-of-its-kind cell and ge…

Bayer AG announced today that BlueRock Therapeutics (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, successfully administe...

Common diabetes drug shows promise as treatment fo…

Metformin is a widely prescribed blood sugar-lowering drug. It is often used as an early therapy (in combination with diet and lifestyle changes) for type 2 diabetes, whi...

Valneva completes Phase 3 trial recruitment for it…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

NIH researchers identify potential new antiviral d…

The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study of cell cultures by researchers at the National Institutes of Heal...

How to obtain immune bovine milk to strengthen the…

Physiologically, milk contains biocomponents that are highly protective against infections. In light of this, the AGR-149-Infectious Diseases group at the University of C...

Novavax COVID-19 vaccine demonstrates 90% overall …

Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate...